^
    Back
    Association details:
    Biomarker:KIT mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EHA 2020
    Title:

    DRUG REPOSITIONING OF CABOZANTINIB TO TREATMENT OF LEUKEMIC CELLS WITH RUNX1-RUNX1T1 AND KIT MUTATION

    Published date:
    05/14/2020
    Excerpt:
    Cabozantinib demonstrated a favorable effect in AML cells harboring t(8;21) and KIT mutation from both in vitro and in vivo aspects.